Intellia Therapeutics Competitors and Similar CompaniesClear all

Intellia Therapeutics's competitors and similar companies include Ionis Pharmaceuticals, 4D Molecular Therapeutics, RD-Biotech and Mustang Bio.

	Intellia Therapeutics Intellia Therapeutics is a genome editing company that caters to the biotechnology industry.	Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.	4D Molecular Therapeutics 4D Molecular Therapeutics is a company focused on creation of gene therapy products to cure genetic diseases.	RD-Biotech RD-Biotech is a biotechnology company that offers customized solutions in genomics, immunology, and cell engineering.	Mustang Bio Mustang Bio is a clinical-stage biopharmaceutical company that specializes in the development of cell and gene therapies.
Founding Date	Founding Date 2014	Founding Date 1989	Founding Date 2013	Founding Date 2002	Founding Date 2015
Type	Type Public	Type Public	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech clinical research healthtech	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech clinical research genetics surgical solutions	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma
Locations	Locations Cambridge, US HQ	Locations Carlsbad, US HQ Vancouver, CA Stuttgart, DE Dublin, IE Dublin, IE Lisboa, PT London, GB see more	Locations Emeryville, US HQ	Locations Besançon, FR HQ Saint Genis Laval, FR	Locations Worcester, US HQ
Employees	Employees 40323% decrease	Employees 1,40231% increase	Employees 22754% increase	Employees 613% increase	Employees 693% decrease
Valuation ($)	Valuation ($) 1.7 b	Valuation ($) 6.3 b	Valuation ($) 426.2 m	Valuation ($) N/A	Valuation ($) 11.2 m
Financial
Revenue (est.)	Revenue (est.) $67.7m (FY, 2025)	Revenue (est.) $943.7m (FY, 2025)	Revenue (est.) $85.2m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Net income	Net income ($412.7m) (FY, 2025)	Net income ($381.4m) (FY, 2025)	Net income ($140.1m) (FY, 2025)	Net income N/A	Net income ($1.9m) (FY, 2025)
Operating ⚠
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products 1 (FY, 2023)	Phase I Trials Products 3 (Q3, 2020)	Phase I Trials Products N/A	Phase I Trials Products N/A